4D Molecular Therapeutics, Inc. SEC filings FDMT
4D Molecular Therapeutics, Inc. has 439 filings in SEC EDGAR's recent list, going back to Aug 13, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 13, 2026 | — |
| CORRESP | Letter to the SEC | May 11, 2026 | — |
| UPLOAD | Letter from the SEC | May 8, 2026 | — |
| EFFECT | Filing | Mar 24, 2025 | — |
| POSASR | Filing | Feb 28, 2025 | — |
| EFFECT | Filing | Aug 15, 2023 | — |
| CORRESP | Letter to the SEC | Aug 11, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2023 | — |
| EFFECT | Filing | Sep 6, 2022 | — |
| CORRESP | Letter to the SEC | Sep 1, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2022 | — |
| EFFECT | Filing | Apr 15, 2022 | — |
| CORRESP | Letter to the SEC | Apr 13, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2022 | — |
| EFFECT | Filing | Oct 28, 2021 | — |
| CORRESP | Letter to the SEC | Oct 26, 2021 | — |
| CORRESP | Letter to the SEC | Oct 26, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2021 | — |
| DRS | Filing | Oct 8, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2020 | — |
| EFFECT | Filing | Dec 10, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 10, 2020 | — |
| CERT | Filing | Dec 10, 2020 | — |
| CORRESP | Letter to the SEC | Dec 8, 2020 | — |
| CORRESP | Letter to the SEC | Dec 8, 2020 | — |
| 8-A12B | Filing | Dec 8, 2020 | — |
| CORRESP | Letter to the SEC | Dec 7, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 2, 2020 | — |
| CORRESP | Letter to the SEC | Nov 17, 2020 | — |
| DRS | Filing | Oct 14, 2020 | — |
| RW | Filing | Jul 21, 2020 | — |
| DRS/A | Filing | Aug 30, 2019 | — |
| DRS | Filing | Aug 2, 2019 | — |
| D | Filing | Sep 11, 2018 | — |
| D | Filing | Oct 19, 2015 | — |
| D | Filing | Aug 13, 2015 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FDMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1650648
- Former names
- 4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.